The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer (OC): A meta-analysis of randomized trials.
 
Riccardo Vida
No Relationships to Disclose
 
Michele Bartoletti
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; MSD; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD
 
Marcella Montico
No Relationships to Disclose
 
Monica Rizzetto
No Relationships to Disclose
 
Giulia Zapelloni
No Relationships to Disclose
 
Serena Corsetti
No Relationships to Disclose
 
Milena Nicoloso
No Relationships to Disclose
 
Simona Scalone
No Relationships to Disclose
 
Anna Del Fabro
No Relationships to Disclose
 
Nicolò Clemente
No Relationships to Disclose
 
Tommaso Occhiali
No Relationships to Disclose
 
Emilio Lucia
No Relationships to Disclose
 
Claudio Reato
No Relationships to Disclose
 
Luca Martella
No Relationships to Disclose
 
Elisabetta Caccin
No Relationships to Disclose
 
Margherita Poletto
No Relationships to Disclose
 
Gianna Tabaro
No Relationships to Disclose
 
Vincenzo Canzonieri
No Relationships to Disclose
 
Antonino Ditto
No Relationships to Disclose
 
Fabio Puglisi
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; Italfarmaco; Lilly; Menarini; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Viatris
Research Funding - AstraZeneca; Eisai; Roche
Travel, Accommodations, Expenses - Amgen; Astrazeneca; Celgene; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pfizer; Roche